PL2262527T4 - Kompozycje do osiągania w surowicy pożądanych poziomów glejowego czynnika wzrostu 2 - Google Patents

Kompozycje do osiągania w surowicy pożądanych poziomów glejowego czynnika wzrostu 2

Info

Publication number
PL2262527T4
PL2262527T4 PL09715322T PL09715322T PL2262527T4 PL 2262527 T4 PL2262527 T4 PL 2262527T4 PL 09715322 T PL09715322 T PL 09715322T PL 09715322 T PL09715322 T PL 09715322T PL 2262527 T4 PL2262527 T4 PL 2262527T4
Authority
PL
Poland
Prior art keywords
compositions
growth factor
plasma levels
achieving desired
glial growth
Prior art date
Application number
PL09715322T
Other languages
English (en)
Polish (pl)
Other versions
PL2262527T3 (pl
Inventor
Haesun Kim
Anthony O. Caggiano
Original Assignee
Acorda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics, Inc. filed Critical Acorda Therapeutics, Inc.
Publication of PL2262527T4 publication Critical patent/PL2262527T4/pl
Publication of PL2262527T3 publication Critical patent/PL2262527T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL09715322T 2008-02-29 2009-03-02 Kompozycje do osiągania w surowicy pożądanych poziomów glejowego czynnika wzrostu 2 PL2262527T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6758908P 2008-02-29 2008-02-29
EP09715322.5A EP2262527B1 (en) 2008-02-29 2009-03-02 Compositions for achieving desired glial growth factor 2 plasma levels

Publications (2)

Publication Number Publication Date
PL2262527T4 true PL2262527T4 (pl) 2017-07-31
PL2262527T3 PL2262527T3 (pl) 2017-07-31

Family

ID=41016663

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16182139.2T PL3120863T3 (pl) 2008-02-29 2009-03-02 Kompozycje do osiągnięcia pożądanych poziomów glejowego czynnika wzrostu 2 w osoczu
PL09715322T PL2262527T3 (pl) 2008-02-29 2009-03-02 Kompozycje do osiągania w surowicy pożądanych poziomów glejowego czynnika wzrostu 2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16182139.2T PL3120863T3 (pl) 2008-02-29 2009-03-02 Kompozycje do osiągnięcia pożądanych poziomów glejowego czynnika wzrostu 2 w osoczu

Country Status (11)

Country Link
US (5) US8410050B2 (enExample)
EP (3) EP2262527B1 (enExample)
JP (2) JP5697455B2 (enExample)
CN (2) CN104645315A (enExample)
AU (1) AU2009217606B2 (enExample)
BR (1) BRPI0908271A2 (enExample)
CA (1) CA2717193C (enExample)
ES (2) ES2811127T3 (enExample)
PL (2) PL3120863T3 (enExample)
RU (3) RU2530650C2 (enExample)
WO (1) WO2009108390A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2262527B1 (en) 2008-02-29 2016-08-03 Acorda Therapeutics, Inc. Compositions for achieving desired glial growth factor 2 plasma levels
CN104623633A (zh) 2008-07-17 2015-05-20 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
RU2501564C2 (ru) 2008-08-15 2013-12-20 Акорда Терапьютикс, Инк. Композиции и способы для лечения во время не острых периодов после неврологического повреждения цнс
CN104984322B (zh) 2009-10-14 2020-09-11 阿寇达医疗有限公司 神经调节蛋白在治疗外周神经损伤中的应用
MX2012013735A (es) * 2010-05-28 2013-04-29 Mind Nrg Sa Isoformas de neuregulina, polipeptidos de neuregulina y usos de los mismos.
WO2012021818A2 (en) * 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use
MX354598B (es) * 2012-03-30 2018-03-12 Acorda Therapeutics Inc Uso de neuregulina para tratar lesion de nervio periferico.
JP7064197B2 (ja) * 2016-09-23 2022-05-10 国立大学法人大阪大学 シュワン細胞分化促進剤及び末梢神経再生促進剤
CN108653274B (zh) * 2017-04-01 2022-09-16 鲁南制药集团股份有限公司 牛蒡子苷元在制备治疗骨髓损伤药物中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7319019B1 (en) 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
EP1229925A2 (en) 1999-11-19 2002-08-14 Axxima Pharmaceuticals Aktiengesellschaft Inhibitors of helicobacter pylori induced gastrointestinal diseases
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
MXPA05012306A (es) 2003-05-16 2006-04-18 Acorda Therapeutics Inc Proteinas de fusion para el tratamiento del snc.
WO2005079458A2 (en) * 2004-02-19 2005-09-01 The Regents Of The University Of California ENHANCEMENT OF Th2-DEPENDENT AND INFLAMMATORY RESPONSE
EP1845985A4 (en) 2005-02-02 2011-10-12 Nexuspharma Inc AMIN DERIVATIVE COMPOSITIONS AND METHODS FOR TREATING VIRUS DISEASES RELATED TO CANCER Aetiology
US7776817B2 (en) 2005-09-02 2010-08-17 Morehouse School Of Medicine Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
US20080003013A1 (en) * 2006-06-30 2008-01-03 Static Control Components, Inc. Cartridge split rail clip
EP2262527B1 (en) 2008-02-29 2016-08-03 Acorda Therapeutics, Inc. Compositions for achieving desired glial growth factor 2 plasma levels
MX2012011473A (es) 2010-04-01 2012-11-16 Procter & Gamble Suavizante de telas.
WO2012021818A2 (en) 2010-08-13 2012-02-16 Georgetown University Ggf2 and methods of use

Also Published As

Publication number Publication date
RU2019110452A (ru) 2020-10-09
ES2613177T3 (es) 2017-05-23
AU2009217606B2 (en) 2015-03-05
US10675331B2 (en) 2020-06-09
US9744215B2 (en) 2017-08-29
ES2811127T3 (es) 2021-03-10
EP3120863A1 (en) 2017-01-25
JP5964920B2 (ja) 2016-08-03
CA2717193C (en) 2022-08-16
US20160367634A1 (en) 2016-12-22
US20130345131A1 (en) 2013-12-26
EP2262527A2 (en) 2010-12-22
CN102026651A (zh) 2011-04-20
JP2015042656A (ja) 2015-03-05
JP5697455B2 (ja) 2015-04-08
RU2014131265A (ru) 2016-02-20
WO2009108390A3 (en) 2010-11-18
CN104645315A (zh) 2015-05-27
BRPI0908271A2 (pt) 2017-06-13
PL3120863T3 (pl) 2021-02-22
AU2009217606A1 (en) 2009-09-03
CA2717193A1 (en) 2009-09-03
JP2011513310A (ja) 2011-04-28
RU2010139906A (ru) 2012-04-10
RU2530650C2 (ru) 2014-10-10
EP2262527B1 (en) 2016-08-03
PL2262527T3 (pl) 2017-07-31
US20180055909A1 (en) 2018-03-01
US20210060128A1 (en) 2021-03-04
CN102026651B (zh) 2015-06-03
US20100029559A1 (en) 2010-02-04
EP3120863B1 (en) 2020-05-06
RU2687097C2 (ru) 2019-05-07
US8410050B2 (en) 2013-04-02
US9272015B2 (en) 2016-03-01
WO2009108390A2 (en) 2009-09-03
EP3750551A1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
IL228826A0 (en) Low voc latex coating preparations
ZA201103926B (en) Stable sulfoximine-insecticide compositions
PL2262527T3 (pl) Kompozycje do osiągania w surowicy pożądanych poziomów glejowego czynnika wzrostu 2
SI2634231T1 (sl) Sestavki
GB0810404D0 (en) Compositions
IL213706A0 (en) Stable insecticide compositions and methods for producing same
ZA201007247B (en) Compositions comprising arnox-inhibitors for the inhibition of reactive oxygen species
GB0812041D0 (en) Compositions
GB0808537D0 (en) Compositions
GB0818804D0 (en) Compositions
SI2470166T1 (sl) Novi sestavki 1-(2-(2,4-dimetil-fenislulfanil)-fenil)piperazina
EP2294199A4 (en) COMPOSITIONS AND METHODS FOR ENHANCING PLANTS
GB0714298D0 (en) Coating compositions
GB0713707D0 (en) Stable compositions
EP2288745A4 (en) COATING COMPOSITIONS
PL2294198T3 (pl) Sposoby i kompozycje do ulepszania roślin
GB0816577D0 (en) Growth factor
HK1152230A (en) Compositions for achieving desired glial growth factor 2 plasma levels
GB0618082D0 (en) Growth factor
HK1166702A (en) Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
HK1148224A (en) Compositions comprising anrnox-inhibitors for the inhibition of reactive oxygen species
GB0922089D0 (en) Compounds, compositions and methods for controlling biofilms
GB0922424D0 (en) Compounds, compositions and methods for controlling biofilms
GB0922087D0 (en) Compounds, compositions and methods for controlling biofilms
HK1166283A (en) Methods and compositions for treating leukemia